Protagonist raises $90M IPO as it upsizes offering

There may be a slightly wider crack in the biotech IPO window this summer as Protagonist Therapeutics announces a larger-than-expected offering.

The Lilly ($LLY)- and Johnson & Johnson ($JNJ)-backed biotech, which is working on the much-anticipated area of peptide-based oral drugs for inflammatory bowel disease, raised $90 million by offering 7.5 million shares at $12, in the middle of its $11 to $13 range.

The Milpitas, CA-based early-stage biotech, which is developing peptide-based oral drugs for inflammatory bowel disease, had originally planned to raise $70 million by offering 5.84 million shares, according to its previous filings. Insiders had been set on buying around $40 million of the IPO.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The biotech, which was founded in 2001 as a spinout from the University of Queensland's Institute of Molecular Biosciences, plans to list on the Nasdaq under the symbol "PTGX."

Turning what are injectable meds for IBD diseases such as Crohn’s disease and ulcerative colitis into oral formulations is no easy task, as the digestive system is a very tricky route for oral peptides. But this would be a much easier route for patient administration, and if successful would create a new way of delivering these kinds of treatments.

Protagonist’s early stage work in the field on its Phase I candidate PTG-100 and preclinical work on PTG-200 have already been enough to garner interest from the venture arms of Eli Lilly and Johnson & Johnson for its $40 million round last year.

- check out the release

Related Article:
Protagonist Therapeutics lands $40M round for an oral peptide IBD drug

Suggested Articles

Acceleron’s sotatercept outdid placebo at reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.

The FDA granted an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to newly diagnosed brain cancer patients.

A new company focusing on sperm rather than egg biology debuted with goals of increasing fertility rates and reducing pregnancy complications.